Due to readers “Ben” and “Theo” for the common updates on Epibiotech (South Korea). Word that Stemore was renamed to Epibiotech in 2021. Since then, the brand new firm has been within the information virtually each month. No firm within the historical past of hair loss is focusing on as many avenues as is Epibiotech (see backside of this put up for a abstract). The highest half of this put up is all updates.
Replace: February 8, 2023
New Epibiotech CEO Interview
A really detailed new interview with Epibiotech CEO Sung Jong-hyeok. The translated title states {that a} highly effective new drug for the elemental therapy of hair loss is coming. Nevertheless, Section 2 trials are but to start for his or her important EPI-001 product. Key quote and picture beneath. Word that they’re engaged on a number of alternative ways to sort out hair loss.
“There are a lot of firms worldwide that conduct analysis on hair loss. However we’re assured that Epibiotech is the one firm that’s growing varied modality therapies primarily based on cells, antibodies, and low-molecular compounds (chemical compounds) and that’s conducting probably the most in-depth analysis.”
“Along with the at the moment main dermal papilla cell-based new hair loss drug, it’s discovering and growing new hair loss therapy targets akin to CXCL12 neutralizing antibody and RIPK1 inhibitor.”
Replace: January 20, 2023
Epibiotech and Novelty The Aristocracy signal an settlement to develop an antibody therapy for hair loss. Epibiotech plans so as to add any new antibodies found by Novelty The Aristocracy to its personal hair loss therapy protocol.
Replace: November 22, 2022
A brand new paper from the CEO on cell remedy for hair regeneration that necessitated my writing a complete weblog put up.
Replace: September 9, 2022
Epibiotech and Humedix to Collectively Develop Hair Loss Remedy
Due to reader “Theo” for the beneath two current updates. On September 7, Epibiotech and Humedix introduced a brand new partnership. The 2 firms will collaborate to additional develop Epibiotech’s hair loss therapy. Humedix appears to be a good cosmetics sector participant, with important expertise in manufacturing injection and platform know-how.
Furthermore, in accordance with the press launch, Humedix can be growing:
“Spheroid tradition know-how via 3D tradition of dermal papilla cells and a scaffold utilizing biopolymer supplies akin to bio-ink associated. The aim is to increase the enterprise into the cell remedy subject by combining 3D bioprinting know-how and biopolymer software know-how.”
Within the article, Epibiotech is described as having experience in 4 key areas:
- Hair papilla cell isolation and cultivation know-how.
- Induced pluripotent stem cell manufacturing know-how.
- Organoid-based hair follicle cell differentiation know-how.
- Gene enhancing know-how.
Additionally of curiosity, in August 2022 Epibiotech employed two new workers members to its management workforce. One among them is described as a vice chairman of the Ministry of Meals and Drug Security. He’s an professional within the medical product subject and a regulatory approval assessment specialist.
Different Latest Updates
Epibiotech CEO Sung Jong-hyeok appears to offer quite a few documented displays at native conferences, universities and extra. Some current highlights:
- Replace: July 12, 2022 — Epibotech human medical trials to begin with a 12 months. One other article from earlier this month states {that a} dermal papilla cell pipeline, was accomplished in June 2022. The corporate “will apply for an IND within the second half of the 12 months and enter Section 1 medical trials in 2023″. Additionally of observe, preclinical work confirmed excellent efficacy. One month after transplantation of human dermal papilla cells into pig pores and skin, the variety of hairs elevated by 40% and the hair thickness by 30%.
- Replace: April 29, 2022 — Epibiotech introduced on April 29, 2022 that it will increase the EPI-001 autologous DPC (dermal hair papilla cell) remedy to off-the-shelf allogeneic therapy.
- Replace: April 21, 2022 — Scientists from Epi Biotech have been concerned in an fascinating new paper. Its conclusion: “Silencing the CXCL12/CXCR4 signaling pathway may be developed for novel hair progress stimulation.”
- Replace: October 5, 2021 — Epibiotech has began producing non-clinical samples of its dermal papilla cell remedy EPI-001 at its cell remedy manufacturing heart.
Epibiotech New Hair Loss Facility
- On June third 2021, Epibiotech and T&R Biotech introduced a partnership to develop a hair loss therapy involving pluripotent stem cells. In keeping with T&R Biotech’s CEO:
“Epibiotech’s dermal papilla cell differentiation know-how and our pluripotent stem cell line will create a mix with excessive synergetic impact.”
- On Might 31, 2021, Epibiotech and its CEO Jong-Hyuk Sung introduced the development of a brand new manufacturing facility at its Songdo headquarters. This GMP facility will likely be used to supply “2,000 self-made dermal papilla cell remedy merchandise yearly”.
Epibiotech’s platform know-how web page is in every single place and a bit complicated. It consists of dermal papilla cell separation and tradition know-how in addition to gene enhancing primarily based hair follicle stem cell manufacturing.
Word that CEO Jong Hyuk Sung is a professor at Yonsei College. This firm was initially based in 2015.
- On April 30, 2021, Epibiotech signed an settlement with Professor Hyung-beom Kim of Yonsei College to develop a hair loss therapy utilizing gene enhancing know-how.
All of this appears a bit too quick and loopy.
Nevertheless, as I outlined in my current put up on Han Bio, South Korea is turning into a world heart for hair loss remedy analysis. On par with the US and Japan if media articles are to be believed.
Renaming from Stemore
I e-mailed Epibiotech to inquire about their know-how and their Might 1, 2021 renaming from Stemore. Under is a part of the reply (with minor corrections) from Dr. Nahyun Choi, the corporate’s director of analysis:
“The identify STEMORE, used beforehand, was primarily based on a concentrate on analysis on hair loss utilizing stem cells when the corporate was based. Nevertheless, our firm is now researching and growing not solely stem cells, but additionally varied hair cells. This consists of dermal papilla cells, and an expanded pipeline to low molecular substances and whitening brokers. Due to this fact, the scope of the analysis and improvement was prolonged to hair and pores and skin. So the corporate identify was modified to Epibiotech after the foreword of epidermal cells.”
Epibiotech Pipeline
In keeping with the corporate’s pipeline web page, they’re engaged on three hair loss merchandise.
- The principle focus is on EPI-001, the autologous dermal papilla hair cell remedy therapy (with paracrine impact). It’s scheduled to enter Section 3 medical trials in 2024.
- The EPI-002 RIPK1 inhibiter (gel or ointment) may even enter Section 3 trials in 2024.
- EPI-005 CXCL12 inhibitor.
- EPI-007 Wnt signaling modulator (with paracrine impact).
They beforehand additionally confirmed EPI-003, an oral PGD2 inhibitor product. It was supposed to complete Section 2 medical trials in early 2025. Now it appears to be have been faraway from the above checklist.
